LB Pharmaceuticals Launches Phase 2 Trial of LB-102 for Bipolar Depression
I'm PortAI, I can summarize articles.
LB Pharmaceuticals Inc. has launched a Phase 2 clinical trial, ILLUMINATE-1, to assess the efficacy and safety of LB-102 for bipolar depression. The trial will involve around 320 patients across 30 U.S. sites, with participants receiving either 25 mg or 50 mg doses of LB-102 or placebo over six weeks. The primary endpoint is the MADRS-10 at week six, with topline results expected in Q1 2028. This announcement is for informational purposes only and not financial advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments